About this trial
This is a prospective registry study based on a standard therapy concept for postoperative simultaneous radiochemotherapy established in Erlangen and elsewhere. The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated. Patients with locally advanced high-grade salivary gland carcinoma after oncological resection are admitted.
Eligibility criteria
Qualifiers
Salivary gland carcinomas of the major and minor salivary glands of the head and neck region
High-grade histology
Successful oncological resection with curative intent
pT3-4 or pN1-3 or Pn1(perineural sheath infiltration) or pT1-2 with scarce or positive resection margin
Disqualifiers
Distant metastases
Other cancer in the last 5 years prior to study inclusion (with the exception of: adequately treated skin cancer (except melanoma) or lentigo maligno or adequately treated carcinoma in situ, in each case without evidence of active disease).
Previous chemotherapy or radiotherapy for salivary gland carcinoma
Previous radiotherapy in the head and neck area
Trial design
Treatments tested in this trial
- simultaneous postoperative radiochemotherapy